In drug development news, FDA granted accelerated approval for Boehringer’s Hernexeos (zongertinib) as a first-line HER2-mutant non-small cell lung cancer treatment in just 44 days, utilizing the ...

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell ...

TARPON SPRINGS, Fla., March 6, 2026 - Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 ...

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...

With the company saying it fills a “critical role in powering the nation’s next chapter of electrification,” Canada’s first large-scale battery manufacturing plant is now officially open for business.

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...

Amatera’s approach is “2x faster and 10x more cost-effective” than industry standards for developing new varieties of perennials, it claims.

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...

JNARDDC advances indigenous metallurgical technologies to reduce India's import dependence, enhancing quality control and ...

Proteomics-informed, genome-edited CHO design increased productivity up to three-fold and titers two-fold, strengthening CLD for novel biologics and biosimilars. Extended culture robustness was ...

OSE will now pivot to focus on late-stage pipeline development of its cancer vaccine, Tedopi and its anti-inflammatory drug, lusvertikimab.